Recently, EGFR-targeted molecular treatment with tyrosine kinase inhibitors, including gefitinib, has shown significant antitumour activity in clinical trials in advanced NSCLC, with early encouraging clinical data reported in cancer of the head and neck, colon, and breast (Caponigro, 2004). This evidence concerns the gene EGFR and non-small cell lung carcinoma.